DDInter1300 DDInter782
Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Nitisinone {u} (Compound) resembles {v} (Compound) Flutamide
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Nitisinone {u} (Compound) binds {v} (Gene) HPD
Nitisinone {u} (Compound) is included by {v} (Pharmacologic Class) Hydroxyphenylpyruvate Dioxygenase Inhibitors
Nitisinone {u} (Compound) causes {v} (Side Effect) Rash erythematous
Nitisinone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Butalbital
Nitisinone (Compound) resembles Flutamide (Compound)
Nitisinone (Compound) resembles Nilutamide (Compound)
Nitisinone (Compound) binds HPD (Gene)
Nitisinone (Compound) is included by Hydroxyphenylpyruvate Dioxygenase Inhibitors (Pharmacologic Class)
Nitisinone (Compound) causes Rash erythematous (Side Effect)
Nitisinone may cause a minor interaction that can limit clinical effects when taken with Modafinil
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Butalbital